Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high rate of non-responsiveness to therapies in ...
Live Science on MSN

Slaying 'zombie cells' in blood vessels could be key to treating diabetes, early study finds

Clearing aged cells from blood vessels could help reduce inflammation, improve blood sugar levels and counter insulin ...

Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day

Insulet Corporation (NASDAQ: PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with ...

Niko Argento, the Blood Concierge—Yes, Blood Concierge—to the Stars, Shares His Secrets

In his first interview, Argento gives 'Vanity Fair' an exclusive look into the booming blood industry. From stem cells, ...
Elle India

Glow Inside Out: How To Eat Chia Seeds For Radiant Skin & Healthy Hair

Discover why chia seeds are the tiny superfood with big beauty energy. Packed with skin friendly nutrients and gut loving ...